Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Researchers Uncover Possible Clue for Radiation Antidote

By Drug Discovery Trends Editor | June 1, 2016

Scientists from the University of Virginia have uncovered promising compounds that could lead to the first antidote for radiation exposure.

The research team analyzed a library containing more than 3,400 existing drugs, vitamins and similar compounds, according to the university’s announcement. The hope was to find a therapy that could keep stem cells alive in order to repair tissue damage induced by resulting radiation exposure.

Next, the team designed 3D computer models to compare the chemical structures of these substances where the results revealed 33 promising compounds that, “significantly reduced cell death in cells exposed to radiation,” reported UPI.

Rapamycin was singled out as the most effective. It’s an immunosuppressive drug that regulates cellular signals like growth, which is why physicians have used this treatment for matters like preventing a transplant patient’s body from rejecting a new organ or stifling cell growth in certain types of cancer. 

READ MORE: Drug Protects Against Effects of Nuclear Radiation Poisoning

However, the researchers admitted that these drugs or compounds won’t be effective on their own.

“A lot of us in this field think it will be a cocktail of things you take,” explained study author Dr. John Lazo, Ph.D., a professor at University or Virginia’s Department of Pharmacology in a statement.

Still, Lazo added that this finding is important because it sheds light on new ingredients needed for this potential cocktail.

There’s currently no treatment for people exposed to high amounts of radiation. Physicians can only provide comfort as rapid cellular deterioration kicks in.

The study was published in the journal ACS Chemical Biology


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50